AS THE GLOBAL RADIOPHARMACEUTICAL MARKET IS PROJECTED TO SURPASS US $ 13 BILLION WITHIN THE NEXT DECADE, THE COMPANIES FEATURED IN THIS REPORT ARE WELL-POSITIONED TO LEAD THE NEXT WAVE OF THERAPEUTIC INNOVATION.
D I S S E C T I N G B U S I N E S S
AS THE GLOBAL RADIOPHARMACEUTICAL MARKET IS PROJECTED TO SURPASS US $ 13 BILLION WITHIN THE NEXT DECADE, THE COMPANIES FEATURED IN THIS REPORT ARE WELL-POSITIONED TO LEAD THE NEXT WAVE OF THERAPEUTIC INNOVATION.
Michael Ward, Global Head of Thought Leadership, Life Sciences and Healthcare, Clarivate, said: " Radioligand therapies are emerging as a cornerstone of precision oncology, combining decades of research in nuclear medicine with the latest innovations in biotechnology. This report identifies the innovators that are pushing the boundaries of what ' s possible in cancer care – and highlights the market, scientific and strategic signals that make them companies to watch."
David Bejker, Chief Executive Officer, Affibody, added: " Radioligand therapies( RLTs) are transforming the promise of precision medicine into reality, enabling treatments that are finely tuned to the unique characteristics of each patient and their tumour, rather than relying on one-size-fits-all solutions. By uniting the precision of targeted drug delivery with the power of radiotherapy, RLTs use tumour-seeking molecules linked to therapeutic radioisotopes to deliver radiation directly to cancer cells, minimising damage to healthy tissue and opening a new frontier in personalised cancer care."
The report offers a detailed view of the evolving RLT landscape, highlighting the science, clinical promise and market momentum behind this precision approach. It profiles emerging innovators; explores key trends in M & A, funding and partnerships; and examines how differentiated R & D strategies and IP positioning set companies apart. The report also addresses challenges in manufacturing and regulation while assessing advances in alpha-emitting isotopes, combination therapies and the infrastructure needed to deliver next-generation radiotherapies at scale.
The Radioligand Companies to Watch are:
• Affibody, founded by researchers at the KTH Royal Institute of Technology and Karolinska Institutet, has a mission of addressing medical needs with pioneering treatments that can improve the lives of patients with serious diseases. As a clinical stage biopharmaceutical company, it has pre-clinical and clinical development programmes in oncology and immunology, with a broad product pipeline focused on developing innovative next-generation biopharmaceutical drugs based on its proprietary technology platform, Affibody molecules.
• Alpha-9 Oncology is developing and advancing a pipeline of differentiated and highly targeted radiopharmaceuticals as potentially life-improving treatments for various malignancies. The company ' s bespoke, iterative process leverages the team ' s deep expertise in modifying peptides, small molecules and small biologics to inform target selection, molecule design, formulation and clinical evaluation.
• Ariceum Therapeutics was launched after the acquisition of the rights for its lead product, satoreotide( SSO110), from Ipsen, which has remained a shareholder in the company. Satoreotide is a proprietary peptide derivative that binds to somatostatin receptor 2( SSTR2), which is overexpressed in neuroendocrine tumours and some aggressive cancers. The company is developing radiopharmaceutical theranostic pairs focusing on aggressive tumours such as small-cell lung cancer( SCLC) and Merkel cell carcinoma( MCC).
• Convergent Therapeutics is developing radioantibodies, by conjugating alpha radionuclides to antibodies that target cancer cells. Its lead candidate, CONV01-a( Ac-225 rosopatamab tetraxetan), is in phase 2 trials for prostate-specific membrane antigen( PSMA)-positive metastatic castrationresistant prostate cancer( mCRPC).
• Perspective Therapeutics, a clinicalstage, radiopharmaceutical company, has adopted a theranostic approach
30 www. intelligenthealth. tech